24小时热门版块排行榜

>论坛更新日志 (999)
>虫友互识 (31)
>导师招生 (20)
>论文投稿 (20)
>考研 (18)
>找工作 (17)
>教师之家 (16)
>基金申请 (15)
>硕博家园 (15)
>考博 (15)
>公派出国 (15)
>博后之家 (13)
>休闲灌水 (12)
>论文道贺祈福 (11)
>有机交流 (10)
>文献求助 (8)

返回列表

当前主题已经存档。

小丸

金虫 (小有名气)

应助: 0 (幼儿园)
金币: 538.6
帖子: 142
在线: 86.1小时
虫号: 241165
注册: 2006-04-09
专业: 药剂学

[交流] FDA马上就要批准的新药

Nuvigil
Cephalon Receives Approvable Letter for Nuvigil (armodafinil)

FRAZER, Pa., May 1, 2006 -- Cephalon, Inc. announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Nuvigil (armodafinil) Tablets. The company submitted a new drug application (NDA) on March 31, 2005, seeking to market Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS) and shift work sleep disorder (SWSD). FDA approval of Nuvigil is contingent upon finalizing the product label.

"We are working closely with the FDA to move this application to an approval and expand our offering of wake-promotion choices for patients," said Dr. Paul Blake, Executive Vice President, Worldwide Medical and Regulatory Operations. "Based on the clinical trials, Nuvigil demonstrated a long duration of effect throughout the waking hours and we are excited at the potential to offer broader options to meet the needs of patients and physicians seeking treatment for excessive sleepiness."

Armodafinil is a single-isomer formulation of modafinil, the active pharmaceutical ingredient contained in Provigil (modafinil) Tablets [C-IV]. Cephalon submitted data from four double-blind, randomized, placebo-controlled studies of Nuvigil in patients with excessive sleepiness associated with either narcolepsy, OSA/HS or SWSD to FDA for evaluation as part of the NDA. In these studies, Nuvigil was generally well tolerated, with a safety profile consistent with that observed in studies of Provigil. The most common adverse effects observed included headache, nausea, dizziness, insomnia and anxiety.

As previously announced, the company submitted additional information to the FDA related to a possible case of Stevens Johnson Syndrome associated with its Sparlon (modafinil) application. In its Nuvigil approvable letter, the FDA indicated that the outcome of its review of this new information will be addressed directly in the label for Nuvigil.

About Excessive Sleepiness (Hypersomnolence)
Excessive sleepiness, medically known as hypersomnolence, is the primary symptom -- and often the most debilitating feature -- experienced by the millions of Americans who suffer from narcolepsy, OSA/HS, and SWSD. Despite this fact, it is estimated that 50 to 90 percent of the time, health care professionals fail to recognize that these patients are suffering from excessive sleepiness. The defining characteristic of excessive sleepiness is a consistent inability to stay awake and alert enough to safely and successfully accomplish tasks of daily living. Persons experiencing excessive sleepiness who seek medical attention typically complain of fatigue, tiredness, lapses of attention, lack of energy, low motivation, difficulty concentrating, disrupted sleep, snoring or difficulties at work.

回复此楼